Antiangiogenic therapies: is VEGF-A inhibition alone enough?

References

• Horn L, Sandler AB. Angiogenesis in the treatment of non-small cell lung cancer. Proc. Am. Thorac. Soc.6(2), 206–217 (2009).
   PubMedGoogle Scholar
• Gutierrez M, Giaccone G. Antiangiogenic therapy in nonsmall cell lung cancer. Curr. Opin. Oncol.20(2), 176–182 (2008).
   PubMedGoogle Scholar
• Los M, Roodhart JM, Voest EE. Target practice: lessons from Phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist12(4), 443–450 (2007).
   PubMed Web of Science ®Google Scholar
• Quesada AR, Medina MA, Alba E. Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer. Bioessays29(11), 1159–1168 (2007).
   PubMed Web of Science ®Google Scholar
• Folkman J. What is the evidence that tumors are angiogenesis dependent? J. Natl Cancer Inst.82(1), 4–6 (1990).
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature407(6801), 249–257 (2000).
   PubMed Web of Science ®Google Scholar
• Greten TF, Korangy F, Manns MP, Malek NP. Molecular therapy for the treatment of hepatocellular carcinoma. Br. J. Cancer100(1), 19–23 (2009).
   PubMed Web of Science ®Google Scholar
• Furnari FB, Fenton T, Bachoo RM et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev.21(21), 2683–2710 (2007).
   PubMed Web of Science ®Google Scholar
• Natale RB, Bodkin D, Govindan R et al. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized Phase II study. J. Clin. Oncol.27(15), 2523–2529 (2009).
   PubMed Web of Science ®Google Scholar
• Prat A, Casado E, Cortes J. New approaches in angiogenic targeting for colorectal cancer. World J. Gastroenterol.13(44), 5857–5866 (2007).
   PubMed Web of Science ®Google Scholar
• Kraeber-Bodere F, Bardet S, Hoefnagel CA et al. Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a Phase I/II clinical trial. Clin. Cancer Res.5(Suppl. 10), 3190s–3198s (1999).
   PubMed Web of Science ®Google Scholar
• Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell15(3), 232–239 (2009).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat. Med.9(6), 669–676 (2003).
   PubMed Web of Science ®Google Scholar
• Kiselyov A, Balakin KV, Tkachenko SE. VEGF/VEGFR signalling as a target for inhibiting angiogenesis. Expert Opin. Investig. Drugs16(1), 83–107 (2007).
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Tumor angiogenesis. N. Engl. J. Med.358(19), 2039–2049 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang Z, Neiva KG, Lingen MW, Ellis LM, Nor JE. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell Death Differ.17(3), 499–512 (2010).
   PubMedGoogle Scholar
• Kopfstein L, Veikkola T, Djonov VG et al. Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and metastasis. Am. J. Pathol.170(4), 1348–1361 (2007).
   PubMed Web of Science ®Google Scholar
• Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J. Biochem. Mol. Biol.39(5), 469–478 (2006).
   PubMedGoogle Scholar
• Pennell NA, Lynch TJ Jr. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist14(4), 399–411 (2009).
   PubMed Web of Science ®Google Scholar
• Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int.56(3), 794–814 (1999).
   PubMed Web of Science ®Google Scholar
• Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin. Cancer Res.12(17), 5018–5022 (2006).
   PubMed Web of Science ®Google Scholar
• Schneider BP, Sledge GW Jr. Drug insight: VEGF as a therapeutic target for breast cancer. Nat. Clin. Pract. Oncol.4(3), 181–189 (2007).
   PubMedGoogle Scholar
• Fontanini G, Vignati S, Boldrini L et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin. Cancer Res.3(6), 861–865 (1997).
   PubMed Web of Science ®Google Scholar
• Fontanini G, Faviana P, Lucchi M et al. A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br. J. Cancer86(4), 558–563 (2002).
   PubMed Web of Science ®Google Scholar
• Yuan A, Yu CJ, Kuo SH et al. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J. Clin. Oncol.19(2), 432–441 (2001).
   PubMed Web of Science ®Google Scholar
• Oka N, Soeda A, Inagaki A et al. VEGF promotes tumorigenesis and angiogenesis of human glioblastoma stem cells. Biochem. Biophys. Res. Commun.360(3), 553–559 (2007).
   PubMed Web of Science ®Google Scholar
• Takano S, Yoshii Y, Kondo S et al. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res.56(9), 2185–2190 (1996).
   PubMed Web of Science ®Google Scholar
• Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat. Rev. Clin. Oncol.6(10), 569–579 (2009).
   PubMed Web of Science ®Google Scholar
• Teramoto S, Arihiro K, Koseki M, Kataoka T, Asahara T, Ohdan H. Role of vascular endothelial growth factor-C and -D mRNA in breast cancer. Hiroshima J. Med. Sci.57(2), 73–78 (2008).
   PubMedGoogle Scholar
• Stacker SA, Caesar C, Baldwin ME et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med.7(2), 186–191 (2001).
   PubMed Web of Science ®Google Scholar
• Achen MG, Williams RA, Minekus MP et al. Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis. J. Pathol.193(2), 147–154 (2001).
   PubMedGoogle Scholar
• Bahram F, Claesson-Welsh L. VEGF-mediated signal transduction in lymphatic endothelial cells. Pathophysiology17(4), 253–261 (2009).
   PubMedGoogle Scholar
• Shibuya M. Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep.41(4), 278–286 (2008).
   PubMed Web of Science ®Google Scholar
• Kong DS, Song SY, Kim DH et al. Prognostic significance of c-Met expression in glioblastomas. Cancer115(1), 140–148 (2009).
   PubMed Web of Science ®Google Scholar
• Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat. Rev. Drug Discov.7(6), 504–516 (2008).
   PubMed Web of Science ®Google Scholar
• Natale RB, Thongprasert S, Greco FA et al. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: a randomized, double-blind Phase III trial (ZEST). J. Clin. Oncol.27(15S), (2009) (Abstract 8009).
   Google Scholar
• De Boer R, Arrieta O, Gottfried M et al. Vandetanib plus pemetrexed versus pemetrexed as second line therapy in patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind Phase III trial (ZEAL). J. Clin. Oncol.27(15S), (2009) (Abstract 8010).
   Google Scholar
• Herbst R, Sun Y, Korfee S et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind Phase III trial (ZODIAC). J. Clin. Oncol.27(18S), (2009) (Abstract CRA8003).
   Google Scholar
• Miller VA, O’Connor PG, Soh C, Kabbinavar F. A randomized, double-blind, placebo-controlled, Phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J. Clin. Oncol.27(18S), (2009) (Abstract LBA8002).
   Google Scholar
• Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med.359(4), 378–390 (2008).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med.356(2), 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med.356(2), 125–134 (2007).
   PubMed Web of Science ®Google Scholar
• Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist12(3), 356–361 (2007).
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350(23), 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Fehrenbacher L, Hainsworth JD et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J. Clin. Oncol.23(15), 3502–3508 (2005).
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol.25(12), 1539–1544 (2007).
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer8(8), 592–603 (2008).
   PubMed Web of Science ®Google Scholar
• Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell15(3), 167–170 (2009).
   PubMed Web of Science ®Google Scholar
• Paez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell15(3), 220–231 (2009).
   PubMed Web of Science ®Google Scholar
• Miletic H, Niclou SP, Johansson M, Bjerkvig R. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms. Expert Opin. Ther. Targets13(4), 455–468 (2009).
   PubMed Web of Science ®Google Scholar
• Jain RK, Duda DG, Willett CG et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol.6(6), 327–338 (2009).
   PubMed Web of Science ®Google Scholar
• Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer3(6), 401–410 (2003).
   PubMed Web of Science ®Google Scholar
• Miller KD, Chap LI, Holmes FA et al. Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol.23(4), 792–799 (2005).
   PubMed Web of Science ®Google Scholar
• Tang TC, Man S, Xu P et al. Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. Neoplasia12(11), 928–940 (2010).
   PubMed Web of Science ®Google Scholar
• Mancuso MR, Davis R, Norberg SM et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest.116(10), 2610–2621 (2006).
   PubMed Web of Science ®Google Scholar
• Bagri A, Berry L, Gunter B et al. Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy. Clin. Cancer Res.16(15), 3887–3900 (2010).
   PubMed Web of Science ®Google Scholar
• Cacheux W, Boisserie T, Staudacher L et al. Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. Ann. Oncol.19(9), 1659–1661 (2008).
   PubMed Web of Science ®Google Scholar
• Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol. Cancer Res.5(3), 203–220 (2007).
   PubMed Web of Science ®Google Scholar
• Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist15(2), 130–141 (2010).
   PubMed Web of Science ®Google Scholar
• Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol.10(6), 559–568 (2009).
   PubMed Web of Science ®Google Scholar
• Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat. Rev. Cancer7(6), 475–485 (2007).
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med.357(26), 2666–2676 (2007).
   PubMed Web of Science ®Google Scholar
• Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist12(6), 713–718 (2007).
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC et al. Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med.355(24), 2542–2550 (2006).
   PubMed Web of Science ®Google Scholar
• Summers J, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma. Oncologist15(1), 104–111 (2010).
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet370(9605), 2103–2111 (2007).
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol.27(28), 4733–4740 (2009).
   PubMed Web of Science ®Google Scholar
• Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (avastin) as treatment of recurrent glioblastoma multiforme. Oncologist14(11), 1131–1138 (2009).
   PubMed Web of Science ®Google Scholar
• Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from Phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol.3(1), 24–40 (2006).
   PubMedGoogle Scholar
• Sandler AB, Johnson DH, Herbst RS. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clin. Cancer Res.10(12 Pt 2), 4258s–4262s (2004).
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P et al. Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised Phase III trial (AVAiL). Ann. Oncol.21(9), 1804–1809 (2010).
   PubMed Web of Science ®Google Scholar
• Kozloff M, Yood MU, Berlin J et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist14(9), 862–870 (2009).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Rivera F, Berry S et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann. Oncol.20(11), 1842–1847 (2009).
   PubMed Web of Science ®Google Scholar
• Grothey A, Sugrue MM, Purdie DM et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J. Clin. Oncol.26(33), 5326–5334 (2008).
   PubMed Web of Science ®Google Scholar
• Allegra CJ, Yothers G, O’Connell MJ et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP Protocol C-08. J. Clin. Oncol.29(1), 11–16 (2010).
   PubMed Web of Science ®Google Scholar
• Dellapasqua S, Bertolini F, Bagnardi V et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J. Clin. Oncol.26(30), 4899–4905 (2008).
   PubMed Web of Science ®Google Scholar
• Garcia-Saenz JA, Martin M, Calles A et al. Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancer. J. Chemother.20(5), 632–639 (2008).
   PubMed Web of Science ®Google Scholar
• Reardon DA, Desjardins A, Vredenburgh JJ et al. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a Phase II study. Br. J. Cancer101(12), 1986–1994 (2009).
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the Phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol.27(20), 3312–3318 (2009).
   PubMed Web of Science ®Google Scholar
• Beck J, Bajetta E, Escudier B et al. A large open label, non comparative Phase III study of the multi-targeted kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma. Presented at: 14th European Cancer Conference. Barcelona, Spain, 23–27 September 2007.
   Google Scholar
• Stadler WM, Figlin RA, McDermott DF et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer116(5), 1272–1280 (2010).
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia–Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol.10(1), 25–34 (2009).
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Trigo JM, Calvo E et al. Activity of a multi-targeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a Phase 2 study (SOGUG-02–06). Lancet Oncol.11(4), 350–357 (2010).
   PubMed Web of Science ®Google Scholar
• Hsu CH, Shen YC, Lin ZZ et al. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J. Hepatol.53(1), 126–131 (2010).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA295(21), 2516–2524 (2006).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multi-targeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol.24(1), 16–24 (2006).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon a in patients with metastatic renal cell carcinoma. J. Clin. Oncol.27(22), 3584–3590 (2009).
   PubMed Web of Science ®Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet368(9544), 1329–1338 (2006).
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J. Clin. Oncol.28(6), 1061–1068 (2010).
   PubMed Web of Science ®Google Scholar
• Hecht JR, Trarbach T, Jaeger E et al. A randomized, double-blind, placebo-controlled, Phase III study in patients (pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). J. Clin. Oncol.23(Suppl. 16), (2005) (Abstract 3).
   PubMedGoogle Scholar
• Koehne C, Bajetta E, Lin E et al. Results of an interim analysis of a multinational randomized, double-blind, Phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2). J. Clin. Oncol.24(Suppl. 18), 3508 (2006) (Abstract 3508).
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Sorensen AG, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell11(1), 83–95 (2007).
   PubMed Web of Science ®Google Scholar
• Joly A. Simultaneous blockade of VEGF and HGF receptors results in potent anti-angiogenic and anti-tumor effects. Eur. J. Cancer Suppl.4(12), 35 (2006).
   Google Scholar
• de Groot JF, Prados M, Urquhart T et al. A Phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse. J. Clin. Oncol.27(15S), (2009) (Abstract 2047).
   PubMedGoogle Scholar
• Kurzrock R, Sherman SI, Pfister D et al. Preliminary results of a Phase 1 study of XL184, a MET, VEGFR2 and RET kinase inhibitor, administered orally to patients with thyroid cancer (TC). Presented at: 34th Annual Meeting of the European Thyroid Association. Lisbon, Portugal, 5–9 September 2009.
   Google Scholar
• Gordon M, Edelman G, Galsky M et al. An adaptive randomized discontinuation trial of XL184 (BMS-907351) in patients with advanced solid tumors J. Clin. Oncol.28(15S), (2010) (Abstract TPS188).
   Google Scholar
• Huynh H, Fargnoli J. Brivanib alaninate. Drugs Future34(11), 881 (2009).
   Google Scholar
• Bhide RS, Lombardo LJ, Hunt JT et al. The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Mol. Cancer Ther.9(2), 369–378 (2010).
   PubMed Web of Science ®Google Scholar
• Jonker DJ, Rosen LS, Sawyer MB et al. A Phase I study to determine the safety, pharmacokinetics, and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. Ann. Oncol. DOI: 10.1093/annonc/mdq599 (2010) (Epub ahead of print).
   Google Scholar
• Raoul J-L, Lencioni R, Baudelet C, Walters I. Tumor response in a Phase 2 study of first- and second-line brivanib in hepatocellular carcinoma (HCC): comparison of modified WHO and modified RECIST criteria. Presented at: 45th Annual Meeting of the European Association for the Study of the Liver. Vienna, Austria, 14–18 April 2010.
   Google Scholar
• Mamluk R, Carvajal IM, Morse BA et al. Anti-tumor effect of CT-322 as an Adnectin inhibitor of vascular endothelial growth factor receptor-2 MAbs.DOI: 10.4161/mabs.2.2.11304 (2010) (Epub ahead of print).
   Google Scholar
• Marathe P, Tang Y, Sleczka B et al. Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J. Pharm. Sci.98(8), 3579–3593 (2010).
   Google Scholar
• Bahleda R, Soria J, Harbison C et al. Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514. J. Clin. Oncol.27(15S), (2009) (Abstract 8098).
   Google Scholar
• Hirawat S, Elfring GL, Northcutt VJ et al. Phase I studies assessing the safety, PK, and VEGF-modulating effects of PTC299, a novel VEGF expression inhibitor. J. Clin. Oncol.25(18S), (2007) (Abstract 3562).
   Google Scholar
• Davis TW, Weetall M, Pagel MD et al. Preclinical efficacy of PTC299, an antiangiogenic candidate in clinical development for the treatment of breast cancer. Presented at: American Society of Clinical Oncology (ASCO) 2007 Breast Cancer Symposium. San Francisco, CA, USA, 7–8 September 2007.
   Google Scholar
• Murukesh N, Dive C, Jayson GC. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br. J. Cancer102(1), 8–18 (2010).
   PubMed Web of Science ®Google Scholar
• Banerjee S, Dowsett M, Ashworth A, Martin LA. Mechanisms of disease: angiogenesis and the management of breast cancer. Nat. Clin. Pract. Oncol.4(9), 536–550 (2007).
   PubMedGoogle Scholar
• Fojo T. Commentary: novel therapies for cancer: why dirty might be better. Oncologist13(3), 277–283 (2008).
   PubMed Web of Science ®Google Scholar
• Ciuffreda L, Di Sanza C, Incani UC, Milella M. The mTOR pathway: a new target in cancer therapy. Curr. Cancer Drug Targets10(5), 484–495 (2010).
   PubMed Web of Science ®Google Scholar
• Page DB, Yuan J, Wolchok JD. Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers. Immunotherapy2(3), 367–379 (2010).
   PubMed Web of Science ®Google Scholar